Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report

Pramod Theetha Kariyanna¹, Naseem A. Hossain¹, Apoorva Jayarangaiah², Nimrah.A. Hossain³, Jonathan Christopher Francois¹, Jonathan D. Marmur¹, Moro O. Salifu¹ and Samy. I. McFarlane^1,

¹Department of Internal Medicine, SUNY-Downstate- Health Science University, Brooklyn, New York, U.S.A.- 11203

²Division of Hematology-Oncology, Department of Internal Medicine, Albert Einstein College of medicine/Jacobi Medical Center, Bronx, New York, U.S.A 10461

³Department of Internal medicine, New York Presbyterian- Brooklyn Methodist Hospital, Brooklyn, New York, U.S.A-11215

Cite this paper

Pramod Theetha Kariyanna, Naseem A. Hossain, Apoorva Jayarangaiah, Nimrah.A. Hossain, Jonathan Christopher Francois, Jonathan D. Marmur, Moro O. Salifu and Samy. I. McFarlane. Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report. American Journal of Medical Case Reports. 2020; 8(7):192-196. doi: 10.12691/AJMCR-8-7-9

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic that started in the Wuhan province of China in December 2019. It is associated with increased morbidity and mortality mainly due to severe acute respiratory syndrome 2 (SARS-Cov-2). Cardiac manifestations related to COVID-19 include demand ischemia, fulminant myocarditis, myocardial infarction and arrhythmias. In this report, we present a case of ST-segment elevation myocardial infarction (STEMI) in a 68-year-old man with COVID-19 who initially presented with chest pain and shortness of breath. Patient's STEMI was managed with pharmaco-invasive strategy with tissue plasminogen activator (t-PA). He then developed acute hypoxic respiratory failure that was managed in the intensive care unit (ICU), together with multi-organ failure from which the patient died 2 days after presentation. Although the pathophysiologic mechanisms of STEMI in COVID-19 patients has not been clearly established, we hypothesize that interrelated pathogenetic factors, that we highlight in this report, can play a role in the development of STEMI, including plaque rupture secondary to systemic inflammation, increased pro-coagulants, endothelial dysfunction, impaired fibrinolysis and impaired oxygen utilization leading to demand/ supply mismatch and myocardial ischemia.

Keywords

COVID-19, ST-segment elevation myocardial infarction (STEMI), Pharmaco-invasive therapy

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation 2020.
[2]	Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020.
[3]	Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020.
[4]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020.
[5]	Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science 2020; 12(1): 8.
[6]	Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2011; 20(1): 62-8.
[7]	Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology 2020.
[8]	Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018; 378(4): 345-53.
[9]	Madjid M, Connolly AT, Nabutovsky Y, Safavi-Naeini P, Razavi M, Miller CC. Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators. Am J Cardiol 2019; 124(1): 44-50.
[10]	Kytomaa S, Hegde S, Claggett B, et al. Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study. JAMA Cardiol 2019; 4(4): 363-69.
[11]	Wang YD, Zhang SP, Wei QZ, et al. [COVID-19 complicated with DIC: 2 cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi 2020; 41(0): E001.
[12]	Chang C-T, Lu Y-H, Chu C-Y, Sheu S-H, Hsu P-C. Two Consecutive Episodes of Acute Myocardial Infarction Occurring in Different Coronary Arteries of a Single Patient with Sepsis. Acta Cardiol Sin 2014; 30(6): 578-81.
[13]	Shibusawa M, Matsumura T, Tsutsumi H, Itou Y, Shibata Y. Unexpected Acute Myocardial Infarction Due to Disseminated Intravascular Coagulation. American Journal of Medical Case Reports 2015; 3(2): 42-45.
[14]	Shi C, Wang C, Wang H, et al. Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study. medRxiv 2020:2020.03.28. 20046144.
[15]	Thachil J. The versatile heparin in COVID-19. J Thromb Haemost 2020.
[16]	Jing, ZC, Zhu HD, Yan XW et al. Recommendations From The Peking Unioun Medical College Hospital for the Management of Acute Myocardial Infarction During the COVID-19 Outbreak. European Heart Journal.